Opportunistic Infections with JAK inhibitors in RA

Save

Winthrop and colleagues have reviewd the occurrence of opportunistic infections (OIs) associated with the use of Janus kinase (JAK) inhibitors in patients with rheumatoid arthritis (RA), showing that Herpez zoster (HZ) was the most common OI reported with JAK inhibitors in clinical trials, althou

2022 EULAR Recommendations for Screening and Prophylaxis of Chronic and Opportunistic Infections

Save

A EULAR Task force has developed recommendations for screening and prophylaxis of chronic and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases (AIIRD).

Women with Rheumatic Disease (11.4.2022)

Save

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.  New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?

Undiagnosed RA During the Pandemic

Save

The number of new diagnoses of rheumatoid arthritis fell by 20% in the first year of the COVID-19 pandemic, new research suggests.

Infections & Lupus (10.28.2022)

Save

Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill. 

Infection: a Leading Cause of Death in Lupus

Save

 Analysis of a national database of hospital discharges from Spain shows that infections accounted for 25% of lupus deaths, making infection the most common cause of death in SLE.

ACR Award Winners (10.21.2022)

Save

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlighted discussion of implantable stimulators, urine proteomics and gut-immune responses to Prevotella in RA.

Vaccination Cut Long COVID Risk for Rheum Patients

Save

Patients with rheumatologic conditions who developed breakthrough COVID-19 infection after vaccination were less likely to suffer long-term symptoms than unvaccinated but otherwise similar patients, researchers said.

Prevotella Immune Response in Both Pre-Clinical & Established RA

Save

In a recent analysis published in Arthritis & Rheumatology, people at risk for rheumatoid arthritis (RA) and those with the disease had elevated blood levels of antibodies against a Prevotella copri (Pc). 

RheumNow Podcast – “That’s Not My Name” (10.7.2022)

Save

Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow.com.

Rheumatoid Arthritis Patients Need to Quit Smoking ASAP

Save

While it is known that smoking ups the risk of developing RA, its effect on outcomes in those with established rheumatoid arthritis (RA) is less known.  A report from an early arthritis registry shows that current smoking increases disease activity and lowers health-related quality of life.

COVID-19 Arthropathy and Myalgia

Save

An online survey of random COVID-19 infected persons shows that arthralgia and myalgia are common consequences to COVID-19 infection.

Heavy Metal Rheumatology (9.23.2022)

Save

Below are this week’s highlights from RheumNow, as discussed by Dr. Jack Cush. Thanks to all of you for your kind comments and great reviews of our weekly podcast. Please let us know how we can improve by emailing me or recording your suggestion using the "Ask Cush Anything" link on our website.

COVID Outcomes in Dermatomyositis

Save

A retrospective study of dermatomyositis (DM) patients with COVID-19, shows that DM patients without comorbidities fair well (with regard to mortality and hospitalisation).

Does Fibromyalgia Need B12? (9.9.2022)

Save

Can we predict the bad outcomes? Like when ITP evolves into SLE; or when psoriasis will develop arthritis; or if Sjogren's will develop lymphoma? Let's dive in and review these journal reports and this past week's news from RheumNow.com.

Goofy But True

Save

Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on RheumNow.com.

FDA Approves BA.4 and BA.5 Omicron COVID Booster Vaccines

Save

Today the FDA authorized the updated Omicron subvariant (BA.4 and BA.5) COVID-19 booster shots manufactured by Pfizer and Moderna; with an anticipated ship/start date of early September 2022. The BA.5 subvariant accounts for more than 88% of U.S. infections.

Influenza Vaccination Recommendations

Save

The CDC has published an update to the recommendations from the Advisory Committee on Immunization Practices (ACIP) on the use of seasonal influenza vaccines in the United States for the 2022-23 season.

2 HIV+ pts with HLH (MAS) successfully Rx w/ JAKi - ruxolitinib. Both had high fevers, severe pancytopenia, hypofibrinogenemia, hypertriglyceridemia, & increased ferritin, BMBx Hemophagocytosis, splenomegaly. https://t.co/yGs7e4Ftgp https://t.co/cv9NX31bZr